The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29
- PMID: 23506887
- DOI: 10.1016/j.mam.2012.05.007
The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29
Abstract
Nucleoside transport in humans is mediated by members of two unrelated protein families, the SLC28 family of cation-linked concentrative nucleoside transporters (CNTs) and the SLC29 family of energy-independent, equilibrative nucleoside transporters (ENTs). These families contain three and four members, respectively, which differ both in the stoichiometry of cation coupling and in permeant selectivity. Together, they play key roles in nucleoside and nucleobase uptake for salvage pathways of nucleotide synthesis. Moreover, they facilitate cellular uptake of several nucleoside and nucleobase drugs used in cancer chemotherapy and treatment of viral infections. Thus, the transporter content of target cells can represent a key determinant of the response to treatment. In addition, by regulating the concentration of adenosine available to cell surface receptors, nucleoside transporters modulate many physiological processes ranging from neurotransmission to cardiovascular activity. This review describes the molecular and functional properties of the two transporter families, with a particular focus on their physiological roles in humans and relevance to disease treatment.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey.Biochem Soc Trans. 2016 Jun 15;44(3):869-76. doi: 10.1042/BST20160038. Biochem Soc Trans. 2016. PMID: 27284054 Review.
-
The equilibrative nucleoside transporter family, SLC29.Pflugers Arch. 2004 Feb;447(5):735-43. doi: 10.1007/s00424-003-1103-2. Epub 2003 Jun 28. Pflugers Arch. 2004. PMID: 12838422 Review.
-
Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins.Xenobiotica. 2008 Jul;38(7-8):995-1021. doi: 10.1080/00498250801927427. Xenobiotica. 2008. PMID: 18668437 Review.
-
Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.Med Res Rev. 2012 Mar;32(2):428-57. doi: 10.1002/med.20221. Epub 2011 Feb 1. Med Res Rev. 2012. PMID: 21287570 Review.
-
Physiological and pharmacological roles of vascular nucleoside transporters.J Cardiovasc Pharmacol. 2012 Jan;59(1):10-5. doi: 10.1097/FJC.0b013e31820eb788. J Cardiovasc Pharmacol. 2012. PMID: 21266914 Review.
Cited by
-
Rheumatological manifestations of H syndrome.Reumatologia. 2024;62(4):294-303. doi: 10.5114/reum/191751. Epub 2024 Sep 16. Reumatologia. 2024. PMID: 39381726 Free PMC article. Review.
-
N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function.Biosci Rep. 2016 Aug 31;36(4):e00376. doi: 10.1042/BSR20160063. Print 2016 Aug. Biosci Rep. 2016. PMID: 27480168 Free PMC article.
-
Modulating pyrimidine ribonucleotide levels for the treatment of cancer.Cancer Metab. 2020 Oct 4;8:12. doi: 10.1186/s40170-020-00218-5. eCollection 2020. Cancer Metab. 2020. PMID: 33020720 Free PMC article. Review.
-
Bioavailability and cytosolic kinases modulate response to deoxynucleoside therapy in TK2 deficiency.EBioMedicine. 2019 Aug;46:356-367. doi: 10.1016/j.ebiom.2019.07.037. Epub 2019 Aug 2. EBioMedicine. 2019. PMID: 31383553 Free PMC article.
-
2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction, 18F-Labeling and Preclinical PET Imaging.Pharmaceuticals (Basel). 2019 Feb 15;12(1):31. doi: 10.3390/ph12010031. Pharmaceuticals (Basel). 2019. PMID: 30781409 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases